计划不错,风险也很高:
“Under the current partnership terms, Sanofi can drop MannKind and Afrezza on Jan. 1, 2016. The product's poor performance in the third quarter and its anticipated drag on future sales, as outlined Thursday, makes that option more likely.”
如果Sanofi终止伙伴协议,MNKD必将遭遇灭顶之灾 。。。。。。